GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rebus Hldgs Inc (OTCPK:RBSH) » Definitions » Debt-to-EBITDA

Rebus Hldgs (Rebus Hldgs) Debt-to-EBITDA : 1.65 (As of Jun. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Rebus Hldgs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Rebus Hldgs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.31 Mil. Rebus Hldgs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. Rebus Hldgs's annualized EBITDA for the quarter that ended in Jun. 2023 was $0.19 Mil. Rebus Hldgs's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 1.65.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Rebus Hldgs's Debt-to-EBITDA or its related term are showing as below:

RBSH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.36   Med: -0.31   Max: 4.67
Current: 0.52

During the past 13 years, the highest Debt-to-EBITDA Ratio of Rebus Hldgs was 4.67. The lowest was -23.36. And the median was -0.31.

RBSH's Debt-to-EBITDA is ranked better than
67.03% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs RBSH: 0.52

Rebus Hldgs Debt-to-EBITDA Historical Data

The historical data trend for Rebus Hldgs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rebus Hldgs Debt-to-EBITDA Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.67 -23.36 -0.31 0.14 -0.33

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 0.25 0.12 -0.19 1.65

Competitive Comparison of Rebus Hldgs's Debt-to-EBITDA

For the Biotechnology subindustry, Rebus Hldgs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rebus Hldgs's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's Debt-to-EBITDA falls into.



Rebus Hldgs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Rebus Hldgs's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.31 + 0) / -0.951
=-0.33

Rebus Hldgs's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.31 + 0) / 0.188
=1.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


Rebus Hldgs  (OTCPK:RBSH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Rebus Hldgs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Rebus Hldgs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Rebus Hldgs (Rebus Hldgs) Business Description

Traded in Other Exchanges
N/A
Address
2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.
Executives
John Robison Montgomery director 7647 BIRCHWOOD HILL RD, CROZET VA 22932
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
Claire Thom director 31200 VIA COLINAS, #200, WESTLAKE VILLAGE CA 91362
Ronald L Shazer officer: Chief Medical Officer C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Christopher P. Lowe director, officer: President and CEO 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Scott Varde Ogilvie director 10880 WILSHIRE BLVD, SUITE 950, LOS ANGELES CA 90024
Bo Jesper Hansen director BIRKENWEG 16, MEGGEN V8 6045
Peter E Grebow director 41 MOORES ROAD, FRAZER PA 19355
Craig A Dionne director, 10 percent owner, officer: CEO,CFO, President 9901 IH 10 WEST, SUITE 800, SAN ANTONIO TX 78230
Russell Richerson 10 percent owner, officer: COO, Secretary 2511 N LOOP 1604 W, SUITE 204, SAN ANTONIO TX 78258
Kihong Kwon 10 percent owner 1015 E. CHAPMAN AVE, SUITE 201, FULLERTON CA 92831